

# Increased COVID-19 Severity among Pregnant Patients Infected with SARS-CoV-2 Delta Variant, France

## Appendix

### Additional Conclusions

Pregnant persons with coronavirus disease (COVID-19) should receive low molecular weight heparin (LMWH) and proven therapies, such as corticosteroids and tocilizumab, on the basis of risk/benefit according to disease severity (*I*). Corticosteroids and tocilizumab were retained as proven therapies for COVID-19 in RECOVERY study results from June 2020 (2) and February 2021 (3). For these reasons, we think that during the first part of period 1 (up to March 1, 2021), standard care was less optimal than the other periods in our study (March 2–November 15, 2021).

### References

1. Nana M, Nelson-Piercy C. COVID-19 in pregnancy. *Clin Med (Lond)*. 2021;21:e446–50. [PubMed https://doi.org/10.7861/clinmed.2021-0503](https://doi.org/10.7861/clinmed.2021-0503)
2. Sterne JAC, Diaz J, Villar J, Murthy S, Slutsky AS, Perner A, et al.; WHO COVID-19 Clinical Management and Characterization Working Group. Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials. *Trials*. 2020;21;734. [PubMed https://doi.org/10.1186/s13063-020-04641-3](https://doi.org/10.1186/s13063-020-04641-3)
3. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet*. 2021;397;1637–45. [PubMed https://doi.org/10.1016/S0140-6736\(21\)00676-0](https://doi.org/10.1016/S0140-6736(21)00676-0)